Education
About Us
Working with TipRanks
Follow Us
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
ATAI Stock Chart & Stats
$3.90
-$0.11(-6.29%)
At close: 4:00 PM EST
$3.90
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$1.15 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)3.56M
Market Cap
$1.42B
Enterprise Value$708.19M
Total Cash (Recent Filing)$114.61M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 26, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding363,214,600
10 Day Avg. Volume3,871,091
30 Day Avg. Volume3,558,174
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.83
Price to Sales (P/S)691.60
P/FCF Ratio-2.58
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue234.66
Enterprise Value/Gross Profit-90.56
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
$13.43Price Target Upside244.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$454.55K
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyPositive Phase 2b results for BPL-003 demonstrated rapid and sustained antidepressant effects with an additive benefit from a second dose, supporting the drug's clinical promise in treatment-resistant depression.
Commercial Rollout ModelShort half-lives of lead assets BPL-003 and VLS-01 enable clinic-based dosing that aligns with the existing SPRAVATO administration network, facilitating a practical commercial roll-out through established treatment centers.
Financial RunwayAvailable cash combined with recent equity financing is expected to fund operating expenses for multiple years, reducing near-term funding risk and supporting continued development across the pipeline.
Bears Say
Regulatory Execution RiskAdvancement to a pivotal Phase 3 program depends on favorable FDA feedback at an End-of-Phase II meeting, creating uncertainty around trial design and program timing.
Research Conflict Of InterestDisclosure that the research provider does and seeks to do business with covered companies creates a potential conflict of interest that could undermine confidence in the objectivity of analyst reports.
Safety ConcernsA reported serious adverse event of suicidal ideation after repeat dosing raises safety concerns that could trigger regulatory review and depress investor sentiment.
ATAI Life Sciences News
ATAI FAQ
What was ATAI Life Sciences’s price range in the past 12 months?
ATAI Life Sciences lowest stock price was $1.15 and its highest was $6.75 in the past 12 months.
What is ATAI Life Sciences’s market cap?
ATAI Life Sciences’s market cap is $1.42B.
When is ATAI Life Sciences’s upcoming earnings report date?
ATAI Life Sciences’s upcoming earnings report date is Mar 26, 2026 which is in 57 days.
How were ATAI Life Sciences’s earnings last quarter?
ATAI Life Sciences released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.165.
Is ATAI Life Sciences overvalued?
According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued.
Does ATAI Life Sciences pay dividends?
ATAI Life Sciences pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on ATAI Life Sciences dividends here
What is ATAI Life Sciences’s EPS estimate?
ATAI Life Sciences’s EPS estimate is -0.11.
How many shares outstanding does ATAI Life Sciences have?
ATAI Life Sciences has 363,214,600 shares outstanding.
What happened to ATAI Life Sciences’s price movement after its last earnings report?
ATAI Life Sciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -2.257%.
Which hedge fund is a major shareholder of ATAI Life Sciences?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ATAI Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.43 (244.36% Upside)
$13.43 (244.36% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $154.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.42%
Trailing 12-Months
Company Description
ATAI Life Sciences
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
ATAI Stock 12 Month Forecast
Average Price Target
$13.43
▲(244.36% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
23.34% Insiders
0.80% Mutual Funds
― Other Institutional Investors
73.75% Public Companies and Individual Investors